Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong
· Delayed Price · Currency is HKD 60.10
+6.15 (11.40%)
Mar 10, 2026, 2:35 PM HKT
HKG:2315 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 1,379 | 980.45 | 716.91 | 533.88 | 354.56 | Upgrade
|
| Revenue Growth (YoY) | 40.63% | 36.76% | 34.28% | 50.58% | 39.84% | Upgrade
|
| Cost of Revenue | - | 204.74 | 206 | 138.21 | 97.3 | Upgrade
|
| Gross Profit | 1,379 | 775.71 | 510.91 | 395.67 | 257.25 | Upgrade
|
| Selling, General & Admin | - | 311.35 | 349.09 | 313.66 | 230.15 | Upgrade
|
| Research & Development | 438.05 | 323.93 | 474.37 | 699.17 | 558.49 | Upgrade
|
| Other Operating Expenses | 752.17 | -9.72 | -21.04 | -12.56 | -12.32 | Upgrade
|
| Operating Expenses | 1,190 | 625.56 | 802.41 | 1,000 | 776.32 | Upgrade
|
| Operating Income | 188.58 | 150.16 | -291.5 | -604.6 | -519.07 | Upgrade
|
| Interest Expense | - | -91.68 | -99.84 | -56.14 | -39.43 | Upgrade
|
| Interest & Investment Income | - | 5.9 | 10.16 | 2.17 | 12.51 | Upgrade
|
| Earnings From Equity Investments | - | -29.75 | -10.03 | -14.77 | -0.4 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 8.67 | 9.08 | 27.37 | -1.78 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.55 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 188.03 | 43.29 | -382.14 | -645.97 | -548.16 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.36 | 0.15 | 19.27 | 2.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.01 | 1.83 | 25.35 | 0.39 | Upgrade
|
| Pretax Income | 188.03 | 42.94 | -380.16 | -601.35 | -545.64 | Upgrade
|
| Income Tax Expense | 14.83 | 9.4 | 2.8 | 0.8 | - | Upgrade
|
| Earnings From Continuing Operations | 173.2 | 33.54 | -382.95 | -602.16 | -545.64 | Upgrade
|
| Minority Interest in Earnings | - | 0.01 | 0 | 0.21 | 0.07 | Upgrade
|
| Net Income | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 | Upgrade
|
| Net Income to Common | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 | Upgrade
|
| Net Income Growth | 416.37% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 403 | 398 | 398 | 381 | 362 | Upgrade
|
| Shares Outstanding (Diluted) | 403 | 398 | 398 | 381 | 362 | Upgrade
|
| Shares Change (YoY) | 1.20% | -0.08% | 4.54% | 5.13% | 180.82% | Upgrade
|
| EPS (Basic) | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 | Upgrade
|
| EPS (Diluted) | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 | Upgrade
|
| EPS Growth | 410.24% | - | - | - | - | Upgrade
|
| Free Cash Flow | - | 174.12 | -203.26 | -543.54 | -564.45 | Upgrade
|
| Free Cash Flow Per Share | - | 0.44 | -0.51 | -1.43 | -1.56 | Upgrade
|
| Gross Margin | 100.00% | 79.12% | 71.27% | 74.11% | 72.56% | Upgrade
|
| Operating Margin | 13.68% | 15.32% | -40.66% | -113.25% | -146.40% | Upgrade
|
| Profit Margin | 12.56% | 3.42% | -53.42% | -112.75% | -153.88% | Upgrade
|
| Free Cash Flow Margin | - | 17.76% | -28.35% | -101.81% | -159.20% | Upgrade
|
| EBITDA | 327.47 | 289.05 | -154.78 | -465.86 | -415.47 | Upgrade
|
| EBITDA Margin | 23.75% | 29.48% | -21.59% | -87.26% | -117.18% | Upgrade
|
| D&A For EBITDA | 138.89 | 138.89 | 136.73 | 138.74 | 103.6 | Upgrade
|
| EBIT | 188.58 | 150.16 | -291.5 | -604.6 | -519.07 | Upgrade
|
| EBIT Margin | 13.68% | 15.32% | -40.66% | -113.25% | -146.40% | Upgrade
|
| Effective Tax Rate | 7.89% | 21.90% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.